Skip to Content
Biotechnology

In blow to new tech, European court decides CRISPR plants are GMOs

A European Union court just ruled that plants altered with gene editing should be subject to the same strict rules that govern older genetically modified plants.

The decision: The Court of Justice of the EU in Luxembourg says in its decision that plants made with “mutagenesis”—which includes gene editing—should follow the same rules as GMOs that contain genes added from other species. “It means for all the new inventions … you would need to go through the lengthy approval process of the European Union,” Kai Purnhagen, an expert at Wageningen University in the Netherlands, told Nature.

The debate: Scientists and industry have been arguing that gene-editing techniques like CRISPR needn’t be highly regulated for safety. They say the plants that result are the same as what you could get from breeding (though a lot faster).

Reap what ye sow: This decision isn’t good for crop R&D in Europe. It may dampen commercial interest in the new technologies. It could also affect global trade in the new plants. “The classification of genome-edited organisms as falling under the GMO Directive could slam the door shut on this revolutionary technology,” Johnathan Napier, a member of Rothamsted Research, a UK crop science institute, told the BBC.

In America: In the U.S., scientists have got their way, and gene-edited soybeans and other crops are being waved forward into the market without stringent safety tests. (For more on the U.S. debate, see our piece from last fall: These Are Not Your Father's GMOs.)

Deep Dive

Biotechnology

How scientists want to make you young again

Research labs are pursuing technology to “reprogram” aging bodies back to youth.

Human brain cells transplanted into baby rats’ brains grow and form connections

When lab-grown clumps of human neurons are transplanted into newborn rats, they grow with the animals. The research raises some tricky ethical questions.

Inside the billion-dollar meeting for the mega-rich who want to live forever

Hope, hype, and self-experimentation collided at an exclusive conference for ultra-rich investors who want to extend their lives past 100. I went along for the ride.

The debate over whether aging is a disease rages on

In its latest catalogue of health conditions, the World Health Organization almost equated old age with disease. Then it backed off.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.